Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIB's Updates & More
by Zacks Equity Research
Regulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Stock Moves -0.28%: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $254.07 in the latest trading session, marking a -0.28% move from the prior day.
Annovis (ANVS) Gains on FDA Authorization for AD Study
by Zacks Equity Research
Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).
Zacks Market Edge Highlights: ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA
by Zacks Equity Research
ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA are part of the Zacks Market Edge article.
Should You Sell Your FANGMAN Stocks?
by Tracey Ryniec
Tracey and Kevin discuss the rocky 2022 stock market and the future of growth stocks.
Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?
by Zacks Equity Research
AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.
Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?
by Zacks Equity Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.
Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates
by Zacks Equity Research
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data
by Ekta Bagri
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Stock Market News for Sep 29, 2022
by Zacks Equity Research
Wall Street closed sharply higher on Wednesday rebounding from a six-day losing streak.
Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study
by Zacks Equity Research
Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.
Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III
by Zacks Equity Research
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Biogen Inc. (BIIB) Stock Moves -0.36%: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $195.38, moving -0.36% from the previous trading session.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $204.83, moving +1.51% from the previous trading session.
Biogen Inc. (BIIB) Up 1.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
by Sanghamitra Saha
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
Eli Lilly's (LLY) Potential New Products Key to Growth
by Zacks Equity Research
Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
by Zacks Equity Research
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus
by Zacks Equity Research
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for MOAT
Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MOAT
AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales. Shares decline in pre-market trading.
Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & More
by Zacks Equity Research
Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.